Compare Cognizant Technology Solutions Corp (CTSH) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Pfizer Inc — how do they compare? Cognizant Technology Solutions Corp trades at $59.33 (market cap $27.03B), while Pfizer Inc trades at $28.01 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 5.9× Cognizant Technology Solutions Corp's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Pfizer Inc for 158 Days on average.
| CTSH | PFE | |
|---|---|---|
Market Cap | $27.03B | $158.56B |
Volume | 9,883,888 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $86.70 | $29.02 |
52-Week Low | $38.73 | $23.67 |
Typical Hold Time | 57 Days | 158 Days |
Enterprise Value | $28.08B | $210.06B |
Dividend Yield | 2.2% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $57.07, down 0.26% on the day, with a bearish technical signal from moving averages. The company reported revenue of $21.11B in 2025 with a net income margin of 10.26%, and recent quarterly earnings have mostly beaten expectations. Analysts maintain a consensus price target of $64.25, with 45.1% recommending a buy. Positive news includes AI partnerships and workplace recognitions, but cash flow trends show volatility.
CTSH presents a mixed outlook: undervalued fundamentals with a P/E of 12.88 and strong profitability support upside potential, but technical weakness and competitive IT spending pressures pose risks. The stock's performance hinges on Q3 2026 earnings results due October 29, 2026, which could validate AI-driven growth initiatives or exacerbate bearish sentiment.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
